| |
NGS is unlocking new possibilities in discovery and diagnostics, but few solutions can keep up with its needs. Access our toolkit to discover how out-of-the-box NGS empowers innovators to hit the ground running. Learn more.
|
|
Today's Big NewsJul 11, 2023 |
|
Sciensus offers the infrastructure, regulatory expertise and experience to navigate the complexities of international distribution and get your rare drugs to hard-to-reach patients. Learn more.
|
|
| By James Waldron Novartis may have insisted earlier this year that it hadn’t given up on anti-TIGIT checkpoint inhibitors, but, now, the Swiss Big Pharma seems to have had a change of heart. |
|
|
|
By Annalee Armstrong BAKX Therapeutics, a small biotech focused on cellular life and death that boasted a partnership with Ipsen, has dissolved. |
By Annalee Armstrong The Fed has paused rate hikes and the major indices are starting to look bullish. Could the summer sun finally be shining on the biotech industry again? |
Sponsored by Clinical Enrollment Using behavioral data science and social algorithms, this boutique biotech agency creates therapeutic-specific and patient-centric content to bypass traditional channels and speak directly to patients. |
By Nick Paul Taylor Bristol Myers Squibb has pulled the trigger on two neuroscience options, paying Prothena $55 million for a global license to a clinical-phase Alzheimer’s disease drug candidate and handing Evotec $40 million for rights to certain late-stage discovery programs. |
Sponsored by OneStudyTeam Hear why sponsors should equip sites with technology that makes securely capturing pre-screening, recruitment, and enrollment data easier. |
By Gabrielle Masson Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs. |
By Annalee Armstrong Astellas is putting up some cash to use one of 4D Molecular Therapeutics’ gene therapy vectors for at least one rare eye disease—but the genetic medicines company is going to have to wait a while to see the true bounty. |
By Max Bayer Viridian is trying to carve out a portion of a simmering market for eye disease treatments, releasing phase 1/2 data on a small group of patients that suggests its candidate could rival Amgen-acquired Horizon. |
By Nick Paul Taylor Hemogenyx Pharmaceuticals now knows what it will take to lift the clinical hold on its CAR-T cell therapy candidate. In its full review letter, the FDA cited a manufacturing issue as the cause of the hold, leading the biotech to identify the source of the problem and develop a solution. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Nick Paul Taylor Early-stage biotech is a secretive world defined by science, reputation and the sometimes eye-watering sums of venture capital money those two attributes can attract. But at some point in their development biotechs need to step out of the shadows and engage in a typically unfamiliar activity: marketing. |
By Fraiser Kansteiner Ivan Cheung, Eisai's American CEO and global Alzheimer's disease officer, will retire at the end of the month. With Cheung headed for the exit, Keisuke Naito—the 34-year-old son of Eisai’s CEO Haruo Naito—has taken up the lead Alzheimer’s mantle, the company said Tuesday. |
By Fraiser Kansteiner With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. That’s good news for Bristol Myers Squibb, which has secured a few more competition-free months for its aging leukemia blockbuster Sprycel. |
By Andrea Park Just a few months after getting back on track after pausing shipments of its Tablo hemodialysis system to secure an updated FDA clearance for at-home use of the technology, Outset Medical is facing another potential regulatory setback. |
By Annie Burky Air pollution has been shown to increase depression symptoms in individuals with bipolar disorder, a new study published by Cambridge University Press found. Insights into the effects of pollution on mental health were gleaned from insights provided by the Juli digital health app |
By Ayla Ellison Innovation, social impact, health equity, breakthroughs and patient advocacy—these are the pillars of the inaugural Fierce 50 project. Meet the esteemed members of the Fierce editorial team who are taking the lead as category chairs. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
